NDATOPICALSOLUTIONPriority Review
Approved
Sep 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
HIBICLENS (chlorhexidine gluconate) by Johnson & Johnson is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. First approved in 1976.
Drug data last refreshed 21h ago
Mechanism of Action
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Indications
Worked on HIBICLENS at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.